

**PUBBLICAZIONI SCIENTIFICHE 2013 DEL CENTRO EMOFILIA E TROMBOSI
ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE
MAGGIORE POLICLINICO**

1. Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, **Cugno M**. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. *Obstet Gynecol* 2013;122:487-489.
2. Asero R, **Tedeschi A, Cugno M**. Treatment of Refractory Chronic Urticaria: Current and Future Therapeutic Options. *Am J Clin Dermatol*. 2013;14:481-8.
3. Baglin T, Hillarp A, **Tripodi A**, Elalamy I, Buller H, Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost* 2013;11:756-60.
4. Bakhtiari K, Kamphuisen PW, **Mancuso ME**, Hamulyak K, Schutgens RE, **Santagostino E**, Meijers JC. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. *Br J Haematol*. 2013;162:827-35.
5. Balduini A, Di Buduo CA, Malara A, **Lecchi A**, Rebuzzini P, Currao M, Pallotta I, Jakubowski JA, Cattaneo M. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. *Haematologica*. 2012;97:1657-65.
6. Belloli L, **Cugno M**, D'Agostino MC, Ughi N, **Tedeschi A**, Respizzi S, Marasini B. Shock wave therapy for systemic sclerosis. *Rheumatol Int* 2013;33:1099-1100.
7. **Bucciarelli P**, De Stefano V, **Passamonti SM**, Tormene D, Legnani C, Rossi E, Castaman G, Simioni P, Cini M, **Martinelli I**. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. *Blood* 2013;122:2555-2561
8. Calizzani G, Vaglio S, Arcieri R, Menichini I, Tagliaferri A, Antoncetti S, Carloni MT, Breda A, **Santagostino E**, Ghirardini A, Tamburrini MR, Morfini M, Mannucci PM, Grazzini G. Models for institutional and professional accreditation of haemophilia centres in Italy. *Haemophilia*. 2013;19:e248-55.
9. Carcao MD, van den Berg HM, Ljung R, **Mancuso ME**; PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. *Blood*. 2013;121:3946-52, S1.
10. **Castelli R**, Cassin R, **Cannavò A, Cugno M**. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. *Clin Lymphoma Myeloma Leuk* 2013;13:1-7.
11. **Castelli R**, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, **Cugno M**. Current and Emerging Treatment Options for Patients with Relapsed Myeloma. *Clin Med Insights Oncol* 2013;7:209-219

12. **Castelli R**, Zanichelli A, Cicardi M, **Cugno M**. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. *Crit Rev Oncol Hematol* 2013;87:323-332.
13. **Castelli R**, Zanichelli A, **Cugno M**. Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic. *Immunopharmacol Immunotoxicol* 2013;35:181-190.
14. Chambost H, **Santagostino E**, Laffan M, Kavakli K; ONE Registry Steering Committee on behalf of the investigators. Real-world outcomes with recombinant factor VIIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. *Haemophilia*. 2013;19:571-7.
15. **Chantarangkul V**, **Biguzzi E**, Asti D, Palmucci C, **Tripodi A**. Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. *Thromb Haemost.* 2013;110:46-52.
16. European Group on von Willebrand Disease (**Peyvandi F.**). Principles of care for the diagnosis and treatment of von Willebrand disease. *Haematologica*. 2013;98:667-74.
17. Cosmi B, Legnani C, Pengo V, Ghirarduzzi A, Testa S, Poli D, Prisco D, **Tripodi A**, Palareti G; for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. *Thromb Haemost* 2013;109:510-6.
18. **Cugno M**, Romano M, Morlacchi LC, Grande R, **Tedeschi A**. Recurrent angioedema associated with secondary eosinophilia. *J Investig Allergol Clin Immunol* 2013;23:129-130.
19. De Stefano V, Grandone E, **Martinelli I**. Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines. *J Thromb Haemost.* 2013;11:1779-81.
20. Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, **Santagostino E**, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. *Blood*. 2013;122:1954-62.
21. ESHRE Capri Workshop Group (**Martinelli I.**). Venous thromboembolism in women: a specific reproductive health risk. *Hum Reprod Update*. 2013;19:471-82.

22. Fabrizi F, Lunghi G, Alongi G, Aucella F, Barbisoni F, Bisegna S, Mangano S, Romei-Longhena G, **Artoni A**, Bettoni G, Messa P, Martin P. Kinetics of Hepatitis B Virus Load During Haemodialysis Sessions and α -Interferon: A Prospective Study. *Kidney Blood Press Res*. 2013;37:286-294.
23. Femia EA, Scavone M, **Lecchi A**, Cattaneo M. Effect of platelet count on platelet aggregation measured by impedance aggregometry (Multiplate™ analyser) and by light transmission aggregometry. *J Thromb Haemost*. 2013;11:2193-6.
24. **Franchi F**, **Biguzzi E**, **Martinelli I**, **Bucciarelli P**, Palmucci C, D'Agostino S, **Peyvandi F**. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. *Thromb Res* 2013;132:e152-e157
25. Franchini M, Coppola A, Rocino A, **Santagostino E**, Tagliaferri A, Zanon E, Morfini M; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. *Semin Thromb Hemost*. 2013;39:752-66.
26. **Garagiola I**, **Mortarino M**, Semprini AE, **Peyvandi F**. Reproductive care in human immunodeficiency virus serodiscordant couples with haemophilia. *Blood Transfus*. 2013;11:469-70.
27. Gianelli U, Fracchiolla NS, **Bucciarelli P**, Ferla V, Boiocchi L, Savi F, Moro A, Reda G, Bosari S, Cortelezzi A. High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes. *Am J Clin Pathol* 2013;139:380-7.
28. Gouw SC1, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, **Mancuso ME**, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. *Blood*. 2013;121:4046-55.
29. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeysens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, **Santagostino E**, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. *N Engl J Med*. 2013;368:231-9.
30. Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort (Santagostino E.). The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. *Blood*. 2013;121:1446-54.
31. Kadir RA, Davies J, Winikoff R, Pollard D, **Peyvandi F**, **Garagiola I**, Pabinger I, Federici AB. Pregnancy complications and obstetric care in women with inherited bleeding disorders. *Haemophilia*. 2013;19 Suppl 4:1-10.

32. Konings J, **Cugno M**, Suffritti C, Ten Cate H, Cicardi M, Govers-Riemslog JW. Ongoing contact activation in patients with hereditary angioedema. *PLoS One* 2013;8:e74043.
33. Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, **Santagostino E**. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. *Haemophilia*. 2013;19:698-705.
34. Lawrie AS, **Stufano F**, **Canciani MT**, Mackie IJ, Machin SJ, **Peyvandi F**. A comparative evaluation of a new automated assay for von Willebrand factor activity. *Haemophilia*. 2013;19:338-42.
35. Lentz SR, Misgav M, Ozelo M, Salek SZ, Veljkovic D, Recht M, Cerqueira M, Tiede A, Brand B, **Mancuso ME**, Seremetis S, Lindblom A, Martinowitz U. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. *Haemophilia*. 2013;19:691-7.
36. **Lotta LA**, Degasperis E, Aghemo A, **Ferrari B**, **Peyvandi F**, Colombo M. Treatment of chronic hepatitis C with pegylated interferon- α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. *Transfus Med*. 2013;23:66-8.
37. **Lotta L**, **Maino A**, **Tuana G**, **Rossio R**, **Lecchi A**, **Artoni A**, **Peyvandi F**. Prevalence of disease and relationships between laboratory phenotype and bleeding severity in platelet primary secretion defects. *Plos One* aprile 2013;8:e60396.
38. **Lotta LA**, **Tuana G**, Yu J, **Martinelli I**, Wang M, Yu F, **Passamonti SM**, **Pappalardo E**, **Valsecchi C**, Scherer SE, Hale W 4th, Muzny DM, Randi G, Rosendaal FR, Gibbs RA, **Peyvandi F**. Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. *J Thromb Haemost*. 2013;11:1228-39.
39. **Lotta LA**, Wu HM, **Musallam KM**, **Peyvandi F**. The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. *Blood Rev*. 2013;27:71-6.
40. **Lotta LA**, Wu HM, **Cairo A**, Bentivoglio G, **Peyvandi F**. Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. *Blood Cells Mol Dis*. 2013;50:59-60.
41. Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, **Peyvandi F**. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. *Thromb Haemost*. 2013;109:488-96.
42. Maggi U, Rossi G, Avesani EC, **Artoni A**, Caprioli F, Napolitano L, **Martinelli I**. Thrombotic storm in a teenager with previously undiagnosed ulcerative colitis. *Pediatrics*. 2013;131:e1288-91.

43. **Maino A**, Algra A, Koudstaal PJ, van Zwet EW, Ferrari MD, Wermer MJ. Concomitant Headache Influences Long-Term Prognosis After Acute Cerebral Ischemia of Noncardioembolic Origin. *Stroke*. 2013;44:2446-50.
44. Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group. Collaborators (2): **Siboni SM**, Laffan M. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. *Blood*. 2013;122:648-57.
45. Mannucci PM, **Mancuso ME**. Investigational drugs for coagulation disorders. *Expert Opin Investig Drugs*. 2013;22:945-53.
46. Marengoni A, Nobili A; Romano V, Tettamanti M, Pasina L, Djade S, Corrao S, Salerno F, Iorio A, Marcucci M, Mannucci PM, **SIMI Investigators**. Adverse clinical events and mortality during hospitalization and 3 months after discharge in cognitively impaired elderly patients. *J Gerontol A Biol Sci Med Sci* 2013;68:419-25.
47. **Martinelli I**. Cerebral vein thrombosis. *Thromb Res*. 2013;131 Suppl 1:S51-4.
48. **Martinelli I, Bucciarelli P, Artoni A**, Fossali EF, **Passamonti SM, Tripodi A, Peyvandi F**. Anticoagulant treatment with rivaroxaban in severe protein S deficiency. *Pediatrics* 2013;132:e1435-9.
49. Martinoli C, Della Casa Alberighi O, Di Minno G, Graziano E, Molinari AC, Pasta G, Russo G, **Santagostino E**, Tagliaferri A, Tagliafico A, Morfini M. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). *Thromb Haemost*. 2013;109:1170-9.
50. Marzano AV, Cozzani E, Fanoni D, De Pità O, Vassallo C, Berti E, Parodi A, Crosti C, **Cugno M**. Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study. *Br J Dermatol* 2013;168:80-84.
51. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, **Cugno M**. Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweet's Syndrome: a Comprehensive Review and Disease Classification Criteria. *Clin Rev Allergy Immunol* 2013;45:202-210.
52. Marzano AV, **Tedeschi A**, Polloni I, Crosti C, **Cugno M**. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. *Clin Exp Immunol* 2013;171:76-81.
53. Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, **Peyvandi F**, van Heerde WL. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. *Thromb Res*. 2013;132:256-62.

54. Motta I, **Artoni A**, Migone De Amicis M, Hu C, Cappellini MD. Prolonged PT and aPTT in a patient with severe proteinuria. *Intern Emerg Med*. 2013;8(7):611-4.
55. **Musallam KM**, Jamali FR, Rosendaal FR, Richards T, Spahn DR, Khavandi K, Barakat I, Demoss B, **Lotta LA, Peyvandi F**, Sfeir PM. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. *Anemia*. 2013;2013:206829.
56. **Musallam KM**, Khalife M, Sfeir PM, Faraj W, Safadi B, Abi Saad GS, Abiad F, Hallal A, Alwan MB, **Peyvandi F**, Jamali FR. Postoperative outcomes after laparoscopic splenectomy compared with open splenectomy. *Ann Surg*. 2013;257:1116-23.
57. **Musallam KM**, Porter JB, Sfeir PM, Tamim HM, Richards T, **Lotta LA, Peyvandi F**, Jamali FR. Raised haematocrit concentration and the risk of death and vascular complications after major surgery. *Br J Surg*. 2013;100:1030-6.
58. **Musallam KM**, Rosendaal FR, Zaatari G, Soweid A, Hoballah JJ, Sfeir PM, Zeineldine S, Tamim HM, Richards T, Spahn DR, **Lotta LA, Peyvandi F**, Jamali FR. Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. *JAMA Surg*. 2013;148:755-62.
59. Ohlmann P, **Lecchi A**, El-Tayeb A, Müller CE, Cattaneo M, Gachet C. The platelet P2Y₁₂ receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. *Purinergic Signal*. 2013;9:59-66.
60. **Pagliari MT, Baronciani L, Garcia Oya I, Solimando M, La Marca S, Cozzi G, Stufano F, Canciani MT, Peyvandi F**. A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A/IIIE). *J Thromb Haemost*. 2013;11:1251-9.
61. Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Violi F, Mannucci PM, on behalf of **REPOSI** Investigators. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. *Drugs Aging* 2013;30:103-12.
62. **Peyvandi F**, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. *Blood*. 2013;122:3423-31.
63. **Peyvandi F, Garagiola I, Seregini S**. Future of coagulation factor replacement therapy. *J Thromb Haemost*. 2013;11 Suppl 1:84-98.
64. **Peyvandi F, Mannucci PM, Valsecchi C, Pontiggia S, Farina C, Retzios AD**. ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates. *Am J Hematol*. 2013;88:895-8.
65. **Peyvandi F, Menegatti M, Palla R**. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. *Semin Thromb Hemost*. 2013;39:579-84.

66. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, **Tripodi A, Chantarangkul V**, Bertero T, De Micheli V, Borghi MO, Meroni PL. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? *Immunol Res* 2013;56:432-8.
67. Protti A, **Lecchi A**, Fortunato F, **Artoni A**, Greppi N, Vecchio S, Fagiolari G, Moggio M, Comi GP, Mistraretti G, Lanticina B, Faraldi L, Gattinoni L. Metformin overdose causes platelet mitochondrial dysfunction in humans. *Crit Care*. 2012;16:R180.
68. **REPOSI** Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med*. 2013;8:509-20.
69. **REPOSI** Investigators. Risk factors for hospital readmission of elderly patients. *Eur J Intern Med* 2013;24:45-51.
70. **REPOSI** Investigators. Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. *Gerontology* 2013;59:307-15.
71. **Rossio R, Ferrari B, Cairo A, Mancini I**, Pisapia G, Palazzo G, **Peyvandi F**. Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. *Blood Transfus*. 2013;11:241-4.
72. Rubattu S, Giusti B, **Lotta LA, Peyvandi F**, Cotugno M, Stanzione R, Marchitti S, Palombella AM, Di Castro S, Rasura M, Mannucci PM, Volpe M. Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. *Eur J Intern Med*. 2013;24:80-2.
73. **Santagostino E**. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance. *Haemophilia*. 2013;19 Suppl 1:8-11.
74. **Santagostino E**. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). *Thromb Res*. 2013;131 Suppl 2:S7-10.
75. **Santagostino E, Fasulo MR**. Hemophilia A and hemophilia B: different types of diseases? *Semin Thromb Hemost*. 2013;39:697-701.
76. **Santagostino E**, Messina M, Tagliaferri A, Iorio A, Morfini M. Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogendale project. *Blood Transfus*. 2013;11:272-80.
77. Scaglione GL, Lancellotti S, Papi M, De Spirito M, Maiorana A, **Baronciani L, Pagliari MT**, Arcovito A, Di Stasio E, **Peyvandi F**, De Cristofaro R. The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. *J Thromb Haemost*. 2013;11:1688-98.
78. Hemophilia Inhibitor Genetics Study Combined Cohort (**Mancuso ME**.) F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. *Haemophilia*. 2013;19:113-8.

79. Simone B, De Stefano V, Leoncini E, Zacho J, **Martinelli I**, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. *Eur J Epidemiol.* 2013;28:621-47.
80. Tarantini L, Bonzini M, **Tripodi A**, Angelici L, Nordio F, Cantone L, Apostoli P, Bertazzi PA, Baccarelli AA. Blood hypomethylation of inflammatory genes mediates the effects of metal-rich airborne pollutants on blood coagulation. *Occup Environ Med.* 2013;70:418-25.
81. **Tripodi A**. The laboratory and the direct oral anticoagulants. *Blood* 2013;121:4032-5.
82. **Tripodi A**. The Laboratory and the New Oral Anticoagulants. *Clin Chem* 2013; 59:353-362.
83. **Tripodi A**. Which Test to Measure the Anticoagulant Effect of Rivaroxaban: The Prothrombin Time Test. *J Thromb Haemost* 2013;11:576-8.
84. **Tripodi A**. Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. *Thrombosis Journal* 2013;11:9.
85. **Tripodi A**, Primignani M. Non-transfusional approach to increase platelet count in patients with cirrhosis and thrombocytopenia. *Hepatology* 2013;58:1177-80.
86. **Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, Gatti L, Mannucci PM, Peyvandi F**. Global coagulation in myeloproliferative neoplasms. *Ann Hematol.* 2013;92:1633-9.
87. **Tripodi A**, Primignani M, **Chantarangkul V, Lemma L**, Jovani M, Rebulli P, Mannucci PM. Global Hemostasis Tests in Patients with Cirrhosis before and after Prophylactic Platelet Transfusion. *Liver International* 2013;33:362-7.
88. **Tripodi A**, Primignani M, **Lemma L, Chantarangkul V**, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. *J Hepatol* 2013;59:265-70.
89. van Geffen M, Mathijssen NC, Holme PA, Laros-van Gorkom BA, van Kraaij MG, Masereeuw R, **Peyvandi F**, van Heerde WL. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. *Thromb Res.* 2013;132:116-22.
90. Vucelić D, Miković D, Rajić Z, Savić N, Budisin Z, Antonijević NM, Obradović S, Jevtić D, **Palla R, Valsecchio C, Peyvandi F**. Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. *Srp Arh Celok Lek.* 2013;141:466-74.
91. Xi M, Makris M, Marcucci M, **Santagostino E**, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. *J Thromb Haemost.* 2013;11:1655-62.